Metabolic Syndrome and Subclinical Hypothyroidism: A Type 2 Diabetes-Dependent Association
| dc.contributor.author | Bermúdez, Valmore | |
| dc.contributor.author | Salazar, Juan | |
| dc.contributor.author | Añez, Roberto | |
| dc.contributor.author | Rojas, Milagros | |
| dc.contributor.author | Estrella, Viviana | |
| dc.contributor.author | Ordoñez, María | |
| dc.contributor.author | Chacín, Maricarmen | |
| dc.contributor.author | Hernández, Juan Diego | |
| dc.contributor.author | Arias, Víctor | |
| dc.contributor.author | Cabrera, Mayela | |
| dc.contributor.author | Cano-Ponce, Clímaco | |
| dc.contributor.author | Rojas, Joselyn | |
| dc.date.accessioned | 2019-01-18T21:17:56Z | |
| dc.date.available | 2019-01-18T21:17:56Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Introduction. Subclinical hypothyroidism (ScH) is an endocrine alteration that is related to cardiovascular risk factors, including those categorized as components of the Metabolic Syndrome (MS). However, findings in prior reports regarding an association between these alterations are inconsistent. The purpose of this study was to determine the relationship between both entities in adult subjects from Maracaibo City, Venezuela. Materials and Methods. The Maracaibo City Metabolic Syndrome Prevalence Study is a descriptive, cross-sectional study with random and multistage sampling. In this substudy, 391 individuals of both genders were selected and TSH, free T3, and free T4 tests were performed as well as a complete lipid profile, fasting glycaemia, and insulin blood values. ScH was defined according to the National Health and Nutrition Examination Survey (NHANES) criteria: high TSH (≥4.12mUI/L) and normal free T4 (0.9-1,9 ng/dL) in subjects without personal history of thyroid disease. MS components were defined according to IDF/AHA/NHLBI/WHF/IAS/IASO-2009 criteria. A multiple logistic regression analysis was used to assess the relationship between MS components and ScH diagnosis. Results. Of the evaluated population, 10.5% (n=41) was diagnosed with ScH, with a higher prevalence in women (female: 13.6% versus male: 7.7%; χ2=3.56, p=0.05). Likewise, 56.1% (n=23) of the subjects with ScH were diagnosed with MS (χ2=4.85; p=0.03), being hyperglycemia the main associated criterion (χ2=11.7; p=0.001). In multivariable analysis, it was observed that the relationship was exclusive with the presence of type 2 diabetes mellitus (T2DM) OR: 3.22 (1.14-9.14); p=0.03. Conclusion. The relationship between ScH and MS in our population is dependent on the presence of hyperglycemia, specifically T2DM diagnosis, findings that vary from those previously reported in Latin American subjects. | eng |
| dc.identifier.issn | 16876334 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12442/2456 | |
| dc.language.iso | eng | eng |
| dc.publisher | Hindawi | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.license | Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional | spa |
| dc.source | Advances in Pharmacological Sciences | eng |
| dc.source.uri | https://doi.org/10.1155/2018/8251076 | spa |
| dc.subject | Metabolic Syndrome | eng |
| dc.subject | Hypothyroidism | eng |
| dc.subject | Diabetes | eng |
| dc.title | Metabolic Syndrome and Subclinical Hypothyroidism: A Type 2 Diabetes-Dependent Association | eng |
| dc.type | article | eng |
| dcterms.references | P. B. Nolan, G. Carrick-Ranson, J. W. Stinear, S. A. Reading, and L. C. Dalleck, “Prevalence of metabolic syndrome and metabolic syndrome components in young adults: A pooled analysis,” Preventive Medicine Reports, vol. 7, pp. 211–215, 2017. View at Publisher · View at Google Scholar · View at Scopus | eng |
| dcterms.references | A. P.Delitala, G. Fanciulli, G. M. Pes, M.Maioli, and G.Delitala, “Thyroid hormones, metabolic syndrome and its components,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 17, no. 1, pp. 56–62, 2017. | eng |
| dcterms.references | K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, “Metabolic syndrome and risk of cancer: a systematic review and meta-analysis,” Diabetes Care, vol. 35, no. 11, pp. 2402–2411, 2012. | eng |
| dcterms.references | A. Cuevas, V. Álvarez, and F. Carrasco, “Epidemic of metabolic syndrome in Latin America,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 18, pp. 134–138, 2011. | eng |
| dcterms.references | M. I. Surks, E. Ortiz, G. H. Daniels et al., “Subclinical thyroid disease: scientific review and guidelines for diagnosis and management,” Journal of the AmericanMedical Association, vol. 291, no. 2, pp. 228–238, 2004. | eng |
| dcterms.references | C. Chang, Y. Yeh, J. L. Caffrey, S. Shih, L. Chuang, and Y. Tu, “Metabolic syndrome is associated with an increased incidence of subclinical hypothyroidism – A Cohort Study,” Scientific Reports, vol. 7, no. 1, 2017. | eng |
| dcterms.references | C. S. Fox, M. J. Pencina, R. B. D’Agostino et al., “Relations of thyroid function to body weight: Cross-sectional and longitudinal observations in a community-based sample,” JAMA Internal Medicine, vol. 168, no. 6, pp. 587–592, 2008. | eng |
| dcterms.references | V. Bermúdez, R. P. Marcano, C. Cano et al., “The maracaibo city metabolic syndrome prevalence study: design and scope,” American Journal of Therapeutics, vol. 17, no. 3, pp. 288–294, 2010. | eng |
| dcterms.references | H. Méndez Castellano and M. C. de Méndez, “Estratificación social y biología humana: método Graffar modificado,” in Arch Ven Pueric Pediatr, vol. 49, pp. 93–104, 1986. | spa |
| dcterms.references | World Health Organization, “Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity,” Geneva: The Organization (WHO Technical Report Series, No. 894), 2000. | eng |
| dcterms.references | Centers for Disease Control and Prevention, “NHANES - NHANES III - Reports and Reference Manuals,” http://www .cdc.gov/nchs/nhanes/nh3rrm.htm. | eng |
| dcterms.references | K. G. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and international association for the study of obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. | eng |
| dcterms.references | J. G. Hollowell, N. W. Staehling, W. D. Flanders et al., “Serum TSH, T4, andThyroid Antibodies in the United States Population (1988 to 1994): NationalHealth and Nutrition Examination Survey (NHANES III),”The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 2, pp. 489–499, 2002. | eng |
| dcterms.references | V. Bermudez, J. Rojas, M. S.Martinez, and etal., “Epidemiologic Behavior and Estimation of an Optimal Cut-Off Point for HomeostasisModel Assessment-2 Insulin Resistance: A Report fromaVenezuelan Population,” International Scholarly Research Notices, vol. 2014,Article ID 616271, 2014. | eng |
| dcterms.references | American Diabetes Association, “Standards of medical care in diabetes—2017: summary of revisions,” Diabetes Care, vol. 40, Supplement 1, pp. S4–S5, 2017. | eng |
| dcterms.references | B. Biondi and D. S. Cooper, “The clinical significance of subclinical thyroid dysfunction,” Endocrine Reviews, vol. 29, no. 1, pp. 76–131, 2008. | eng |
| dcterms.references | V. Bermúdez, M. Cabrera, C. Chavez et al., “Comportamiento epidemiol´ogico del hipotiroidismo subclínico y su asociación con factores de riesgo cardiometab´olicos en individuos adultos del municipioMaracaibo, Venezuela,” Revista Latinoamericana de Hipertensión, vol. 8, no. 1, pp. 1–8, 2013. | spa |
| dcterms.references | J. D. J. Garduño-Garcia, U. Alvirde-Garcia, G. López-Carrasco et al., “TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects,” European Journal of Endocrinology, vol. 163, no. 2, pp. 273–278, 2010. | eng |
| dcterms.references | M. M. Pesic,D.Radojkovic, S.Antic,R.Kocic, andD. Stankovic- Djordjevic, “Subclinical hypothyroidism: Association with cardiovascular risk factors and components of metabolic syndrome,” Biotechnology & Biotechnological Equipment, vol. 29, no. 1, pp. 157–163, 2015. | eng |
| dcterms.references | S. Khatiwada, S. K. Sah, R. KC, N. Baral, and M. Lamsal, “Thyroid dysfunction in metabolic syndrome patients and its relationship with components of metabolic syndrome,” Clinical Diabetes and Endocrinology, vol. 2, no. 1, 2016. | eng |
| dcterms.references | A. Ogbera, O. Dada, and S. Kuku, “The metabolic syndrome in thyroid disease: A report from Nigeria,” Indian Journal of Endocrinology and Metabolism, vol. 16, no. 3, p. 417, 2012. | eng |
| dcterms.references | M. Uzunlulu, E. Yorulmaz, and A. Oguz, “Prevalence of subclinical hypothyroidism in patients with metabolic syndrome,” Endocrine Journal, vol. 54, no. 1, pp. 71–76, 2007. | eng |
| dcterms.references | C. Wang, “The Relationship between Type 2 Diabetes Mellitus and RelatedThyroidDiseases,” Journal of Diabetes Research, vol. 2013, Article ID 390534, 9 pages, 2013. | eng |
| dcterms.references | M. V´azquez, J. Rojas, and V. Bermudez, “Comportamiento epidemiológico del hipotiroidismo en pacientes con diabetes mellitus tipo 2 en la ciudad de Loja – Ecuador,” Revista Latinoamericana de Hipertension, vol. 8, no. 4, pp. 95–102, 2013. | spa |
| dcterms.references | L. Chaker, S. Ligthart, T. I. M. Korevaar et al., “Thyroid function and risk of type 2 diabetes: A population-based prospective cohort study,” BMC Medicine, vol. 14, no. 1, 2016. | eng |
| dcterms.references | S. Furukawa, S. Yamamoto, Y. Todo et al., “Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetesmellitus,” Endocrine Journal, vol. 61, no. 10, pp. 1011–1018, 2014. | eng |
| dcterms.references | C. Han, X. He, X. Xia et al., “Subclinical hypothyroidism and type 2 diabetes: a systematic review and meta-analysis,” PLoS ONE, vol. 10, no. 8, Article IDe0135233, 2015. | eng |
| dcterms.references | M. Hage, M. S. Zantout, and S. T. Azar, “Thyroid disorders and diabetes mellitus,” Journal ofThyroid Research, vol. 2011, Article ID 439463, 7 pages, 2011. | eng |
| dcterms.references | A. Cabanelas, P. C. Lisboa, E. G. Moura, and C. C. Pazos Moura, “Leptin acutemodulation of the 5 -deiodinase activities in hypothalamus, pituitary and brown adipose tissue of fed rats,” Hormone and Metabolic Research, vol. 38, no. 8, pp. 481–485, 2006. | eng |
| dcterms.references | S. Topsakal, E. Yerlikaya, F. Akin, B. Kaptanoglu, and T. Er¨urker, “Relation with HOMA-IR and thyroid hormones in obese Turkish women with metabolic syndrome,” Eating and Weight Disorders, vol. 17, no. 1, pp. e57–e61, 2012. | eng |
| dcterms.references | C. Han, C. Li, J. Mao, and etal., “High Body Mass Index Is an Indicator of Maternal Hypothyroidism, Hypothyroxinemia, andThyroid-Peroxidase Antibody Positivity during Early Pregnancy,” BioMed Research International, Article ID 351831, 2015. | eng |
| dcterms.references | E. Maratou, D. J. Hadjidakis, A. Kollias et al., “Studies of insulin resistance in patients with clinical and sub clinical hypothyroidism,” European Journal of Endocrinology, vol. 160, no. 5, pp. 785–790, 2009. | eng |
| dcterms.references | H. J. Baskin, R. H. Cobin, D. S. Duick et al., “American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism,” Endocrine Practice, vol. 8, no. 6, pp. 457– 469, 2002. | eng |
| dcterms.references | E. Bilic-Komarica, A. Beciragic, and D. Junuzovic, “Effects of treatment with L-thyroxin on glucose regulation in patients with subclinical hypothyroidism,” Medical Archives, vol. 66, no. 6, pp. 364–368, 2012. | eng |